The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals

被引：0
|
作者：
Sigrid Haeggström
Magnus Ingelman-Sundberg
Svante Pääbo
Hugo Zeberg
机构：
[1] Karolinska Institutet,Department of Neuroscience
[2] Karolinska Institutet,Department of Physiology and Pharmacology
[3] Max Planck Institute for Evolutionary Anthropology,Department of Evolutionary Genetics
[4] Okinawa Institute of Science and Technology,Human Evolutionary Genomics Unit
来源：
The Pharmacogenomics Journal | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Genetic variation in genes encoding cytochrome P450 enzymes influences the metabolism of drugs and endogenous compounds. The locus containing the cytochrome genes CYP2C8 and CYP2C9 on chromosome 10 exhibits linkage disequilibrium between the CYP2C8*3 and CYP2C9*2 alleles, forming a haplotype of ~300 kilobases. This haplotype is associated with altered metabolism of several drugs, most notably reduced metabolism of warfarin and phenytoin, leading to toxicity at otherwise therapeutic doses. Here we show that this haplotype is inherited from Neandertals.
引用
收藏
页码：247 / 249
页数：2
相关论文
共 50 条
  • [31] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
  • [32] The Inhibitory Effect of Telmisartan on the Metabolism of Arachidonic Acid by CYP2C9 and CYP2C8: An in Vitro Study
    Kato, Yuka
    Mukai, Yuji
    Rane, Anders
    Inotsume, Nobuo
    Toda, Takaki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (09) : 1409 - 1415
  • [33] Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population
    Annan Sudarsan Arun Kumar
    Srinivasamurthy Suresh Kumar
    Gurusamy Umamaheswaran
    Ramasamy Kesavan
    Jayaraman Balachandar
    Chandrasekaran Adithan
    Pharmacological Reports, 2015, 67 : 97 - 101
  • [34] Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population
    Kumar, Annan Sudarsan Arun
    Kumar, Srinivasamurthy Suresh
    Umamaheswaran, Gurusamy
    Kesavan, Ramasamy
    Balachandar, Jayaraman
    Adithan, Chandrasekaran
    PHARMACOLOGICAL REPORTS, 2015, 67 (01) : 97 - 101
  • [35] COMPARISON OF THE EFFECT OF CHRONIC KIDNEY DISEASE (CKD) ON PHARMACOKINETICS OF CYP1A2, CYP2C8, CYP2C9 AND CYP2C19 SUBSTRATES
    Tan, M-L
    Yoshida, K.
    Zhao, P.
    Zhang, L.
    Galetin, A.
    Huang, S-M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S10 - S11
  • [36] Application of Vivid™ fluorogenic substrates for the in vitro assessment of CYP2C9*1, CYP2C9*2 and CYP2C9*3 metabolism
    Thompson, DV
    Marks, BD
    Goossens, TA
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 153 - 153
  • [37] Analysis of CYP2C9 promotor variations and possible links to the CYP2C9*2 and CYP2C9*3 exon variants.
    Schubert, C
    Cubic, I
    Kirchheiner, J
    Brockmöller, J
    Roots, I
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S98 - S98
  • [38] Analysis of CYP2C8, CYP2C9, CYP2C18 and CYP2C19 mRNA expression in human liver, small intestine, skin and leucocytes
    Laepple, F
    Griese, EU
    Zanger, U
    Thon, KP
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (04) : R783 - R783
  • [39] The Relationship Between Warfarin Resistance and CYP2C9*2 and CYP2C9*3 Variations
    Kirac, Deniz
    Yaman, Aysun Erdem
    Doran, Tansu
    Altunok, Elif Cigdem
    MEDICAL JOURNAL OF BAKIRKOY, 2021, 17 (03) : 209 - 213
  • [40] Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico
    Sanchez-Pozos, Katy
    Rivera-Santiago, Carolina
    Helena Garcia-Rodriguez, Maria
    Guadalupe Ortiz-Lopez, Maria
    Itzel Pena-Espinoza, Barbara
    de los Angeles Granados-Silvestre, Maria
    Llerena, Adrian
    Menjivar, Marta
    PHARMACOGENOMICS, 2016, 17 (17) : 1881 - 1889
12345